



March 6, 2019

Via E-mail: AGO.highcostprescriptiondrugs@vermont.gov

Re: New Drug Introduction Report Pursuant to 18 V.S.A. § 4637(c)

To Whom It May Concern:

On February 8, 2019, and pursuant to 18 V.S.A. § 4637(b), Teva Pharmaceuticals USA, Inc. (“Teva”) submitted a new drug introduction notice for VIGABATRIN 500MG TABLETS 100 (NDC 00591-3851-01) (the “Product”). Teva now provides the following additional information pursuant to 18 V.S.A. § 4637(c).

- 1. US and international marketing and pricing plans used at launch:** Teva declines to provide this information in accordance with 18 V.S.A. § 4637(d).
- 2. Estimated volume of patients:** Estimated count of approximately 5,000 patients per year.
- 3. Whether the FDA granted breakthrough therapy designation or priority review:** The Product received priority review but did not receive a breakthrough therapy designation.
- 4. Date and price of acquisition:** Not applicable; Teva developed the Product.

* * * *

Teva provides this report consistent with its understanding and interpretation of 18 V.S.A. § 4637 and its provisions. In providing this report, Teva does not waive any rights it may have at law or in equity with respect to 18 V.S.A. § 4637, its interpretation, and/or its application to Teva or any of its affiliates, now or in the future. Teva, on behalf of itself and its affiliates, expressly reserves all such rights.

Thank you for your consideration.

Sincerely,

A handwritten signature in black ink that reads "Brian Savage".

Brian Savage
General Counsel, US Generics
Teva Pharmaceuticals USA, Inc.